When objective response to neoadjuvant chemotherapy (weekly T × 12 followed by fluorouracil, doxorubicin, cyclophosphamide (FAC) × 4) was examined in relation to the established molecular subtypes of breast cancer, Rouzier et al. identified the highest rates of pCR among the BLBC (45%; CI 24–68%) and erbB2+ (45% CI 23–68%) subgroups. The gene discussed is ERBB2; the disease is breast cancer.